NHS Overrides Drug Rejection Through Secret Price Deal

The NHS approved the ovarian cancer drug mirvetuximab soravtansine on June 4, reversing NICE's rejection. The shift came after NHS England negotiated new pricing terms with manufacturer AbbVie—details kept confidential. This pattern, where health systems sidestep cost-effectiveness standards for rare cancers, raises concerns about whether drug access decisions remain transparent to the public.